BioTrends Research Group, Inc. concludes that Extavia, a treatment for Multiple Sclerosis, has been pushed to the back burner on the heels of a new product launch by Novartis called Gilenya. Gilenya is the first of its kind oral disease modifying agent used to combat MS. Since Gilenya hit the market, there has been a [...]